Advances in meningioma therapy

Norden, Andrew D.; Drappatz, Jan; Wen, Patrick Y.

doi:10.1007/s11910-009-0034-5

Cited by 83 publications

(80 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of tumor location, a gross total resection is not always safe or possible. Adjuvant radiotherapy and radiosurgery are also part of the clinical management of meningiomas (4)(5)(6). Given the scarcity of therapeutic options for patients with meningioma, there is a definite need for better and more efficient therapeutic options, in particular for higher-grade and recurrent tumors.…”

Section: Introductionmentioning

confidence: 99%

NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Baía

Caballero

et al. 2013

Cancer Immunology Research

View full text Add to dashboard Cite

Meningiomas are the most common primary intracranial tumors. Surgical resection remains the treatment of choice for these tumors. However, a significant number of tumors are not surgically accessible, recur, or become malignant, necessitating the repetition of surgery and sometimes radiation. Chemotherapy is rarely used and is generally not recognized as an effective treatment. Cancer/testis (CT) genes represent a unique class of genes, which are expressed by germ cells, normally silenced in somatic cells, but activated in various cancers. CT proteins can elicit spontaneous immune responses in patients with cancer and this feature makes them attractive targets for immunotherapy-based approaches. We analyzed mRNA expression of 37 testis-restricted CT genes in a discovery set of 18 meningiomas by reverse transcription PCR. The overall frequency of expression of CT genes ranged from 5.6% to 27.8%. The most frequently expressed was NY-ESO-1, in 5 patients (27.8%). We subsequently analyzed NY-ESO-1 protein expression in a larger set of meningiomas by immunohistochemistry and found expression in 108 of 110 cases. In some cases, NY-ESO-1 expression was diffused and homogenous, but in most instances it was heterogeneous. Importantly, NY-ESO-1 expression was positively correlated with higher grade and patients presenting with higher levels of NY-ESO-1 staining had significantly worse disease-free and overall survival. We have also shown that NY-ESO-1 expression may lead to humoral immune response in patients with meningioma. Considering the limited treatment options for patients with meningioma, the potential of NY-ESO-1-based immunotherapy should be explored. Cancer Immunol Res; 1(5); 296-302. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Baía

Caballero

et al. 2013

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…Due to the fact that meningiomas express progesterone receptors in up to 67% and somatostatin receptors in up to 100 %, chemotherapeutical studies focus on the development of receptor antagonists to stop tumor growth (Wen et al 2010;Whittle et al 2004). Yet, trials of various drugs have not been very successful (Norden et al 2009, Schulz et al 2011. Anyway, some data from ongoing and recently closed studies are still lacking, e.g.…”

Section: Chemotherapymentioning

confidence: 99%

“…Anyway, some data from ongoing and recently closed studies are still lacking, e.g. hydroxyurea (Norden et al 2009;Newton et al 2007). …”

Section: Chemotherapymentioning

confidence: 99%

“…Knowledge in underlying genetic alterations as well as in epigenetic pathologies is increasing and may help to identify genetic risk factors for tumour recurrence and malignancy (Bethke et al 2008;Norden et al 2009). Within the last years, new target therapy options such as hormone receptor antagonists and anti-angiogenetic drugs (e.g.…”

Section: Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Surgical Management of Skull Base Meningiomas – An Overview

Fischer¹,

Brokinkel²

2012

Meningiomas - Management and Surgery

View full text Add to dashboard Cite

“…Entretanto, a média dos escores do KPS dos doentes incluídos na presente casuística foi de 89,4% (DP = 5,3% De acordo com outras publicações, houve melhora da sintomatologia entre 20% e 69% dos doentes com MSC tratados com RCE ou RCEF (Kondziolka et al, 2008;Kimball et al, 2009 (Pollock et al, 2003;Selch et al, 2004;Bauman et al, 2007;Norden et al, 2009 (Kondziolka et al, 2008). As complicações observadas no presente estudo foram pouco marcantes e similares às relatadas por outros autores (Litré et al, 2009 (Kondziolka et al, 2008;Song et al, 2012 10.…”

Section: Gráfico 7 -unclassified

Radiocirurgia e radioterapia estereotática no tratamento de meningeomas sintomáticos do seio cavernoso

Correa¹

View full text Add to dashboard Cite

Advances in meningioma therapy

Cited by 83 publications

References 74 publications

NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Surgical Management of Skull Base Meningiomas – An Overview

Radiocirurgia e radioterapia estereotática no tratamento de meningeomas sintomáticos do seio cavernoso

Contact Info

Product

Resources

About